<meta http-equiv="Content-Type" content="text/html;charset=utf-8" /><!DOCTYPE doctype html>
<html class xmlns="http://www.w3.org/1999/xhtml">
 <head>  <link href="./style.css" rel="stylesheet" type="text/css"/><title id="pageTitle">
   # 276 Postherpetic Neuralgia
  </title>
 </head>
 <body>
   <div id="mainBody">
    <!--/pageTopArea -->
    <div id="contentArea">
     <div id="contentContainer">
      <!--/toolContainer -->
      <div id="centerZone">
 		<div id="titleBarContainer">
 			<h1># 276 Targeted Cancer Therapies Part 1</h1>
       </div>
       <!--/titleBarContainer -->
       <p>
         <strong>
          Authors:
         </strong>
         Helen Gharwan, MD, Dr Sci and Hunter Groninger, MD
        </p>
        <p>
         <strong>
          Background
         </strong>
         Targeted cancer therapy is an umbrella term for a diverse group of newer antineoplastic agents developed to block the growth and progression of malignant cells by interfering with intracellular pathways responsible for tumor growth. (1) Their use in treating cancer is expanding rapidly, including for patients with far-advanced disease who may not otherwise have been eligible for traditional cytotoxic chemotherapies. (2) This Fast Fact reviews types of targeted cancer therapies and side effects seen with tyrosine kinase inhibitors. Part 2 addresses monoclonal antibody targeted agents.
        </p>
 <p>
         <strong>
          Pharmacology
         </strong>
        While conventional chemotherapies generally interfere nonselectively with the proliferation of all rapidly dividing cells in the body, targeted agents are meant to block one or more molecules that are essential for the proliferation of cancer cells. They can be categorized into two main groups.<br />
<em>Small molecule drugs</em> are primarily tyrosine kinase inhibitors (TKIs). These are orally administered drugs with potential to inhibit various tyrosine kinases (TKs), intracellular  enzymes that are mutated or overexpressed in malignant cells.3 TKIs competitively inhibit adenosine triphosphate at the catalytic binding site of the enzymes, compete with the substrate of TKs, or bind at alternative sites and induce a conformational change resulting in inhibition of the enzyme activity. Side effect profiles of the TKIs depend on the roles the individual enzymes play in intracellular signaling and overall cell function. On-target toxicities are related to the primary pharmacological effects of the drugs and occur when TKIs inhibit molecules/pathways that are required for normal function of cells at sites other than the cancer cells; while off-target toxicities are due to secondary pharmacological effects of the drugs and occur when molecules/pathways are inhibited that are not intended to be targeted by the TKI.4 Table 1 summarizes many TKIs’ clinical use and toxicities.<br />
<em>Monoclonal antibodies</em> (mAbs) are larger than TKIs and unable to enter cells. They are designed to bind selectively to specific tumor-associated antigens on the surface of cancer cells. MAbs are administered intravenously and can be used either in an unconjugated form or conjugated via a linker to cytotoxic molecules to help enhance their tumor selectivity and their anticancer effect.5 MAbs are more specific than TKIs, but due to their complex development process, more
expensive than TKIs. 
        </p>
        <p>
         <strong>
          Common side effects of TKIs
         </strong>
         All TKIs can cause cytopenias and gastrointestinal side effects such as nausea/vomiting.3 Some TKIs cause headaches, muscle cramps, periorbital edema, and induce/worsen symptoms of depression. Since TKIs are teratogenic, female patients of reproductive age should take appropriate measures to prevent pregnancy and/or stop breastfeeding during therapy. Although patients may be evaluated for specific risks prior to therapy (e.g., premorbid cardiovascular disease), no guidelines exist for prophylaxis against TKI toxicities. Side effects should be managed with general symptom management principles.6 Two main classes of side effects are discussed below.<br /><br />
<em>Cardiovascular toxicities</em><br />
Mild to moderate hypertension requires only observation. For severe hypertension there are no specific antihypertensive drugs recommended, except that nondihydropyridine calcium channel blockers (e.g., verapamil, diltiazem), which inhibit CYP3A4, should be avoided in conjunction with sunitinib and pazopanib. (7)<br />
Left ventricular dysfunction manifestations range from asymptomatic EKG findings to severe congestive heart failure. Predisposing factors include prior anthracycline therapy and TKI-induced hypertension. (8)<br />
Pulmonary arterial hypertension (e.g., from dasatinib) is generally reversible with discontinuation. (8)<br />
QTc interval prolongation occurs variably; whether this complication is classwide is unknown. Although specific guidelines are lacking, caution is advised in patients with underlying cardiac disease and when other QTc prolonging drugs are administered. (8) Obtaining a baseline EKG is a common, although empiric, practice.<br /><br />

<em>Dermatologic toxicities</em>
<li>A variety of nonspecific skin toxicities may occur with TKIs, including dry skin, hair color changes, skin discoloration, acral erythema, subungual hemorrhages, an aceiform rash, and hand-foot syndrome (HFS), beginning several weeks after therapy initiation.</li>
<li>Prior to initiating therapy, patients are advised to use sunscreens, enhance skin moisturizing, and avoid tight fitting shoes. (9)</li>
<li>No specific management guidelines exist for the acneiform rash; expert opinion recommends topical antibiotics (e.g., clindamycin 1% + / - benzoyl peroxide) or oral antibiotics (e.g., tetracycline, minocycline) and continuation of TKI therapy.9 HFS, or palmar-plantar erythrodysesthesia, often arises within the first six weeks of therapy and worsens with continued chemotherapy. (10)</li>
<li>HFS usually resolves within two to four weeks of drug therapy interruption, and usually recurs if TKI is introduced at the same dose.  Expert opinion suggests National Cancer Institute Grade 1 HFS (erythema without pain) be treated with keratolytics and emollients; Grade 2 HFS (skin changes and/or pain) requires topical corticosteroids and topical or systemic analgesics (including opioids); Grade 3 (ulcerative dermatitis and/or pain impeding function) requires TKI interruption and dose reduction. Other supportive therapies in use—all empiric—include pyridoxine, COX-2 inhibitors, gabapentinoids, systemic corticosteroids, regional cooling, and transdermal nicotine. (10)</li>
        </p>
        <p>
        Table 1. Side Effect Proﬁles of 20 FDA-Approved TKIs to Treat Malignancies (7)
        <table style="border:1px solid black;border-collapse:collapse;">
			<tr>
                <th style="border:1px solid;">Drug</th>
                <th style="border:1px solid;">Indications</th>
                <th style="border:1px solid;">Common side effects</th>
                <th style="border:1px solid;">Serious side effects</th>
                <th style="border:1px solid;">Comments</th>
    		</tr>
            <tr>
           	  <td  style="border:1px solid;">Axitinib (Inlyta)</td>
                <td  style="border:1px solid;">RCC</td>
                <td  style="border:1px solid;">Hypertension, HFS, diarrhea, nausea, vomiting, transaminitis</td>
                <td  style="border:1px solid;">Hemorrhages, arterial/ venous thrombosis, pulmonary embolism</td>
                <td  style="border:1px solid;"></td>
            </tr>
            <tr>
           	  <td  style="border:1px solid;">Bosutinib (Bosulif)</td>
                <td  style="border:1px solid;">Philadelphia chromosome positive CML</td>
                <td  style="border:1px solid;">Diarrhea, nausea, vomiting, abdominal pain, skin rash, thrombocytopenia</td>
                <td  style="border:1px solid;">Prolonged QT interval, pericardial/pleural effusion, hepatotoxicity, acute renal failure</td>
                <td  style="border:1px solid;"></td>
            </tr>
            <tr>
           	  <td  style="border:1px solid;">Cabozantinib (Cometriq)</td>
                <td  style="border:1px solid;">Metastatic medullary thyroid cancer</td>
                <td  style="border:1px solid;">Electrolyte abnormalities (calcium, phosphorus), hypertension, cytopenias, transaminitis, hair color change, fatigue</td>
                <td  style="border:1px solid;">HFS, arterial and venous thromboembolism, cytopenias, gastrointestinal perforation and ﬁstula formation</td>
                <td  style="border:1px solid;">Discontinue drug before elective surgeries or dental procedures</td>
            </tr>
            <tr>
           	  <td  style="border:1px solid;">Crizotinib  (Xalkori)</td>
                <td  style="border:1px solid;">ALK-positive NSCLC</td>
                <td  style="border:1px solid;">Vision disorder, diarrhea, nausea, vomiting, constipation, edema</td>
                <td  style="border:1px solid;">Prolonged QT interval, transaminitis and hepatotoxicity, neutropenia, pulmonary embolism, pneumonitis</td>
                <td  style="border:1px solid;"></td>
            </tr>
            <tr>
           	  <td  style="border:1px solid;">Dabrafenib  (Taﬁnlar)</td>
                <td  style="border:1px solid;">Malignant melanoma with BRAF V600E mutation</td>
                <td  style="border:1px solid;">Hyperglycemia, hypophosphatemia, headache, hyperkeratosis, alopecia, HFS, arthralgias, fever</td>
                <td  style="border:1px solid;">New primary skin cancer (malignant melanoma, squamous cell cancer), pancreatitis, interstitial nephritis</td>
                <td  style="border:1px solid;">Should be taken on an empty stomach</td>
            </tr>
            <tr>
           	  <td  style="border:1px solid;">Dasatinib  (Spycel)</td>
                <td  style="border:1px solid;">Imatinib-resistant CML, Philadelphia chromosome positive acute myelogenous leukemia</td>
                <td  style="border:1px solid;">Body ﬂuid retention, rash, headache, dyspnea, electrolyte abnormalities</td>
                <td  style="border:1px solid;">Congestive heart failure, pericardial/ pleural effusion, prolonged QT interval, hemorrhagic colitis</td>
                <td  style="border:1px solid;"></td>
            </tr>
            <tr>
           	  <td  style="border:1px solid;">Erlotinib  (Tarceva)</td>
                <td  style="border:1px solid;">NSCLC, pancreatic cancer (in combination with gemcitabine)</td>
                <td  style="border:1px solid;">Edema, diarrhea, nausea, vomiting, loss of appetite, abdominal pain, rash, alopecia, cough, depression, fatigue, fever</td>
                <td  style="border:1px solid;">Rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, cardiac dysrhythmia, myocardial infarction, syncope, bowel obstruction, interstitial lung disease, corneal perforation/ ulceration, abnormal eyelash growth</td>
                <td  style="border:1px solid;">Cigarette smoking may require dose adjustment. Increased rash severity has been associated with better drug response and clinical outcome (4)</td>
            </tr>
            <tr>
           	  <td  style="border:1px solid;">Geﬁtinib  (Iressa)</td>
                <td  style="border:1px solid;">NSCLC</td>
                <td  style="border:1px solid;">Acneiform or pustulous rash, folliculitis; paronychial inﬂammation, diarrhea</td>
                <td  style="border:1px solid;">Respiratory compromise (especially in patients with prior chemotherapy or radiation), interstitial lung disease, tumor hemorrhage</td>
                <td  style="border:1px solid;">Coadministration of aspirin reduces the rash. Monitor INR frequently in patients who also take Warfarin</td>
            </tr>
            <tr>
           	  <td  style="border:1px solid;">Imatinib (Gleevec)</td>
                <td  style="border:1px solid;">GIST, certain types of leukemias</td>
                <td  style="border:1px solid;">Rash, diarrhea, vomiting, arthralgia, edema, headache, weight gain</td>
                <td  style="border:1px solid;">Left ventricular dysfunction, congestive heart failure, cardiac tamponade, cardiogenic shock, gastrointestinal perforation, sensorineural hearing loss, acute respiratory failure, increased intracranial pressure</td>
                <td  style="border:1px solid;">Cardiac complications are usually seen in elderly with preexisting cardiovascular disease</td>
            </tr>
            <tr>
           	  <td  style="border:1px solid;">Lapatinib (Tykerb)</td>
                <td  style="border:1px solid;">HER-2-positive breast cancer</td>
                <td  style="border:1px solid;">Diarrhea, nausea, vomiting, HFS, rash, anemia, transaminitis, hyperbilirubinemia, fatigue</td>
                <td  style="border:1px solid;">Prolonged QT interval, left ventricular dysfunction, hepatotoxicity, interstitial lung disease</td>
                <td  style="border:1px solid;">Hepatotoxicity may necessitate drug discontinuation</td>
            </tr>
            <tr>
            	<td  style="border:1px solid;">Nilotinib (Tasigna)</td>
                <td  style="border:1px solid;">CML</td>
                <td  style="border:1px solid;">Pruritus, night sweats, rash, diarrhea, nausea, vomiting, arthralgias, myalgias, headache, cough, fatigue, alopecia</td>
                <td  style="border:1px solid;">Prolonged QT interval, cytopenias, gastrointestinal hemorrhage, intracranial hemorrhage</td>
                <td  style="border:1px solid;">Must be taken on an empty stomach, as concomitant intake of food may increase the risk of QT prolongation</td>
            </tr>
            <tr>
           	  <td  style="border:1px solid;">Pazopanib (Votrient)</td>
              <td  style="border:1px solid;">RCC, soft tissue sarcoma</td>
              <td  style="border:1px solid;">Hypertension, changes of hair color, diarrhea, nausea, vomiting, loss of appetite, arthralgias, myalgias, headache, electrolyte abnormalities, dyspnea, fatigue</td>
              <td  style="border:1px solid;">Hemorrhage, hepatotoxicity, congestive heart failure, myocardial infarction, hypothyroidism, reversible posterior leukoencephalopathy syndrome, pneumothorax</td>
                <td  style="border:1px solid;">Cardiovascular and hepatic toxicities are usually seen within the ﬁrst 18 weeks of treatment</td>
            </tr>
            <tr>
           	  <td  style="border:1px solid;">Ponatinib (Iclusig)</td>
                <td  style="border:1px solid;">TKI-resistant CML, TKI-resistant Philadelphia chromosome positive acute lymphoblastic leukemia</td>
              <td  style="border:1px solid;">Hypertension, abdominal pain, constipation, nausea, headache, fever</td>
              <td  style="border:1px solid;">Arterial and venous thromboembolism, hepatotoxicity, body ﬂuid retention, congestive heart failure, cardiac arrhythmias, myocardial infarction, cytopenias, pancreatitis</td>
                <td  style="border:1px solid;">Coadministration of drugs that increase gastric pH may lead to decreased ponatinib bioavailability and exposure</td>
            </tr>
            <tr>
           	  <td  style="border:1px solid;">Regorafenib (Stivarga)</td>
              <td  style="border:1px solid;">Colorectal cancer, GIST</td>
              <td  style="border:1px solid;">Hypertension, electrolyte abnormalities, acral erythema, cytopenias, transaminitis, hyperbilirubinemia, difﬁculty speaking, proteinuria, fever</td>
              <td  style="border:1px solid;">Hemorrhage, hepatotoxicity, hypertension, myocardialinfarction, gastrointestinalﬁstula, gastrointestinalperforation</td>
                <td  style="border:1px solid;">&nbsp;</td>
            </tr>
            <tr>
           	  <td  style="border:1px solid;">Ruxolitinib (Jakaﬁ or Jakavi)</td>
                <td  style="border:1px solid;">Myeloﬁbrosis</td>
              <td  style="border:1px solid;">Contusion, dizziness, headache, anemia, thrombocytopenia</td>
              <td  style="border:1px solid;">Cytopenias; herpes zoster or serious infections may occur</td>
                <td  style="border:1px solid;">Dose adjustment may be required dependent on the platelet count</td>
            </tr>
            <tr>
           	  <td  style="border:1px solid;">Sorafenib (Nexavar)</td>
                <td  style="border:1px solid;">RCC, hepatocellular cancer</td>
                <td  style="border:1px solid;">Diarrhea, nausea, loss of appetite, abdominal pain, electrolyte abnormalities, fatigue, rash, HFS, alopecia</td>
                <td  style="border:1px solid;">Hemorrhage, congestive heart failure, myocardial infarction, prolongation of QT interval, severe skin reactions</td>
                <td  style="border:1px solid;"></td>
            </tr>
            <tr>
            	<td  style="border:1px solid;">Sunitinib (Sutent)</td>
                <td  style="border:1px solid;">RCC, GIST, pancreatic neuroendocrine tumors</td>
                <td  style="border:1px solid;">Diarrhea, nausea, vomiting, loss of appetite, altered taste sensation, yellow skin discoloration, rash, elevation of uric acid, hypothyroidism, cough, fatigue</td>
                <td  style="border:1px solid;">Thrombocytopenia, tumor hemorrhage, prolongation of QT interval, left ventricular dysfunction, tissue necrosis, aseptic necrosis of jaw bone, hemoptysis, hepatotoxicity</td>
                <td  style="border:1px solid;">Hypertension and proteinuria improve with dose reduction or discontinuation of the drug</td>
            </tr>
            <tr>
            	<td  style="border:1px solid;">Trametinib (Mekinist)</td>
                <td  style="border:1px solid;">Malignant melanoma with BRAF V600E or V600K mutation</td>
                <td  style="border:1px solid;">Rash, diarrhea, transaminitis, anemia, lymphedema, hypoalbuminemia</td>
                <td  style="border:1px solid;">Cardiomyopathy, hemorrhages, dermatologic toxicities, interstitial lung disease, pneumonitis, visual disturbances</td>
                <td  style="border:1px solid;"></td>
            </tr>
            <tr>
            	<td  style="border:1px solid;">Vandetanib (Caprelsa)</td>
                <td  style="border:1px solid;">Medullary thyroid cancer</td>
                <td  style="border:1px solid;">Rash, acne, hypertension, hypocalcemia, transaminitis, headache, fatigue</td>
                <td  style="border:1px solid;">Prolonged QT interval, ischemic stroke, interstitial lung disease, respiratory failure/arrest</td>
                <td  style="border:1px solid;">Coadministration of antiarrhythmic drugs should be avoided</td>
            </tr>
            <tr>
            	<td  style="border:1px solid;">Vemurafenib (Zelboraf)</td>
                <td  style="border:1px solid;">Malignant melanoma with BRAF V600E mutation</td>
                <td  style="border:1px solid;">Nausea, arthralgias, alopecia, photosensitivity, pruritus, rash, skin papillomas</td>
                <td  style="border:1px solid;">Squamous cell carcinoma, HFS, prolonged QT interval, ophthalmologic reactions (iritis, photophobia, retinal vein occlusion)</td>
                <td  style="border:1px solid;"></td>
            </tr>
        </table>
</p>
        <p>
         <strong>
          References
         </strong>
        </p>
 <ol>
   <li>Krause DS, Van Etten RA: Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172–187.</li>
         <li>Amir E, Seruga B, Martinez-Lopez J, et al.: Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol 2011;29:2543–2549.</li>
         <li>Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors: A review on pharmacology, metabolism and side effects. Curr Drug Metab 2009;10:470–481.</li>
         <li>Shah DR, Shah RR, Morganroth J: Tyrosine kinase inhibitors: Their on-target toxicities as potential indicators of efficacy. Drug Saf 2013;36:413–426.</li>
         <li>Chari RVJ: Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc Chem Res 2008;41:98–107.</li>
         <li>Mendez-Vidal MJ, Ortega EM, Pino AM, Valderrama BP, Vician R: Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma. Cancer Metastasis Rev 2012;31:S19–S27.</li>
         <li>Thomson Reuters (Healthcare): Micromedex Healthcare Series. Greenwood Village, CO: Thomson Reuters (Healthcare). Last accessed August 9, 2013.</li>
         <li>Shah RR, Morganroth J, Shah DR: Cardiovascular safety of tyrosine kinase inhibitors: With a special focus on cardiac repolarisation (QT Interval). Drug Saf 2013;36: 295–316.</li>
         <li>Huang X, Patel S, Ahmed N, Seiter K, Liu D: Severe toxicity of skin rash, fever and diarrhea associated with imatinib: Case report and review of skin toxicities associated with tyrosine kinase inhibitors. Drug Des Devel Ther 2009;2:215–219.</li>
         <li>Lipworth AD, Robert C, Zhu AX: Hand-foot syndrome (handfoot skin reaction, palmar-plantar erythrodysesthesia): Focus on sorafenib and sunitinib. Oncology 2009;77:257–271.</li>
        </ol>
        </p>
 <p>
        Address correspondence to: <br />
Hunter Groninger, MD<br />
NIH Pain and Palliative Care Service<br />
Clinical Research Center Building<br />
10, Room 2-1733<br />
10 Center Drive<br />
Bethesda, MD 20892<br />
E-mail: <a href="mailto:hunter.groninger@nih.gov">hunter.groninger@nih.gov</a><br />
240 FAST FACTS AND CONCEPTS <!--/mainBody -->
 </p>
 </body>
</html>
